Key Takeaways
- Researchers at Simon Fraser University have developed a faster method for discovering antiviral drugs.
- The new approach allows for the production of extensive libraries of nucleosides in weeks, compared to traditional months-long processes.
- Initial tests against HIV revealed three compounds with efficacy comparable to existing treatments.
Innovative Method Accelerates Antiviral Drug Discovery
As global health faces increasing challenges from novel viral threats like COVID-19 and Ebola, a team of researchers from Simon Fraser University (SFU) has announced a breakthrough that significantly shortens the timeline for antiviral drug discovery. Led by chemistry professor Robert Britton, the study highlights a new method that could enhance the development of antiviral therapies.
Currently, the process of identifying new antiviral treatments involves screening large libraries of molecular candidates for potential effectiveness. This methodology previously enabled pharmaceutical companies such as Merck & Co. and Gilead Sciences to discover early COVID-19 treatments. However, the size of these libraries has traditionally been restricted due to the complexities of chemistry involved in synthesizing antiviral compounds.
The method described in the research, published in the journal Science, leverages a single, scalable building block as its foundation. This approach utilizes a light-driven chemical reaction to incorporate various nucleobases to the core structure, enabling rapid generation of a comprehensive library of over 70 nucleic acids (NAs) within weeks.
Britton notes that the ability to screen a larger array of compounds substantially boosts the chances of finding effective antiviral drugs. “In an emerging outbreak, the more compounds you can screen, the better your chances of finding something effective,” he explains. The researchers’ technique allows for the creation of libraries that are 10 to 100 times larger than those developed through previous methods.
Upon screening this extensive library against HIV at the Pantophlet Laboratory at SFU, under the leadership of health sciences professor Ralph Pantophlet, three of the new compounds demonstrated antiviral activity comparable to that of existing HIV treatments. Britton emphasizes that many compounds were entirely new, with a few others having been synthesized previously, but involving significantly longer processes for their development.
The research team’s collaboration with Merck has not only laid the groundwork for these advancements but has also underscored the urgent need for a diverse array of antiviral options. The scarcity of effective antiviral drugs contributes to public health crises during viral outbreaks, making this new discovery particularly impactful.
In summary, the innovative methodology developed by Britton and his team presents a game-changing advancement in the field of antiviral drug discovery. By significantly reducing the time and complexity involved in creating libraries of antiviral compounds, this approach holds the potential to lead to new treatments that could be critical in combating future viral outbreaks.
The content above is a summary. For more details, see the source article.